The Sputnik Light vaccine is based on the human adenovirus serotype 26, which is the first component of the Sputnik V vaccine, the first immunizer developed globally to fight Covid-19, and whose administration Argentina authorized in December 2020.

The National Administration of Drugs, Foods and Medical Devices registered Sputnik V based on Russian clinical trial data, without applying additional studies in Argentina.

Analyses by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology showed that Sputnik Light, administered as as single dose, has a 70-percent efficacy against infections from the Delta variant of the coronavirus during the first three months after vaccination.

Studies conducted by that Russian scientific institution based on data from 28,000 citizens in Moscow showed that the Sputnik Light vaccine is 75-percent effective among subjects under the age of 60.

Used as a booster dose for other vaccines to fight the Delta variant, the immunizer is close to the efficacy of the Sputnik V vaccine, which is more than 83-percent efficient against the virus and more than 94 percent against hospitalization, the RDIF stated.

jg/iff/jf/mml